BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 7,604 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 7,604 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

BioLife Solutions Price Performance

BLFS traded up $1.13 during trading on Thursday, reaching $26.11. The stock had a trading volume of 404,267 shares, compared to its average volume of 384,028. The stock has a 50 day moving average of $24.78 and a two-hundred day moving average of $23.66. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -24.63 and a beta of 1.91. BioLife Solutions, Inc. has a 1-year low of $14.50 and a 1-year high of $28.88.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently modified their holdings of the company. Stifel Financial Corp raised its position in BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after acquiring an additional 670 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of BioLife Solutions by 4.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after purchasing an additional 700 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in BioLife Solutions by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 753 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new position in BioLife Solutions during the third quarter valued at about $28,000. Institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

BLFS has been the topic of several recent research reports. Benchmark reiterated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday. HC Wainwright cut their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. TD Cowen raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.